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The Global Sepsis Alliance’s Quality Improvement Committee (QIC) aims to collate 
sepsis quality improvement tools from different jurisdictions and resource settings onto the 
Global Sepsis Alliance (GSA) website for open access. The publication of the Sepsis-3 
definitions resulted in a number of concerns related to its impact on the work of QI initiatives 
that focus on early identification and treatment of sepsis and prompted statements by the 
GSA,  HYPERLINK "http://www.global-sepsis-alliance.org" www.global-sepsis-alliance.org 
and the Surviving Sepsis campaign (SSC), www.survivingsepsis.org. 
Thus, in this document we aim to assess the new sepsis definitions1 in the context of 
quality improvement initiatives. We briefly describe the major changes and their potential 
advantages and disadvantages, in the context of the six domains of usefulness2 used by the 
Consensus Definitions Task Force in creating the definitions, and from the point of view of 
two of the major stakeholder groups: those involved in clinical care and in QI programs.  
 
 
WHAT ARE THE MAJOR CHANGES? 
 
The 3rd International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) 
were published in February 2016.1 The new definitions are intended to improve the clarity of 
definitions for clinical care, surveillance, quality improvement and audit, and research. The 
Task Force recognize that involved stakeholders might weigh differently relative importance 
of the six domains of usefulness of a definition (reliability, content validity, construct 
validity, criterion validity, measurement burden and timeliness).2  
The new definitions were primarily based on clinical criteria (construct validity) and 
on their ability to predict outcome (criterion validity assessed by predictive validity) as 
assessed by a retrospective analysis of large databases from North America with a small 
contribution from one database in Germany.     
Sepsis is now defined as “life threatening organ dysfunction caused by a dysregulated 
host response to infection”. The clinical diagnosis of organ dysfunction is made using the 
Sequential (Sepsis –related) Organ Failure Assessment Score (SOFA), with an increase in the 
score of ≥ 2 from baseline consequent to the infection being diagnostic. Where baseline is not 
known, it is assumed to be zero. The presence of systemic inflammatory response syndrome 
(SIRS) criteria is no longer required for the diagnosis.  Septic shock is defined as “a subset of 
sepsis with particularly profound circulatory, cellular and metabolic abnormalities associated 
with a greater risk of mortality than sepsis alone” The diagnostic criteria for septic shock are 
a “vasopressor requirement required to maintain a MAP of  > 65mmHg and a serum lactate 
level > 2mmol/L in the absence of hypovolaemia”.  
A new score was also described, the quick SOFA (qSOFA), developed as a bedside 
tool to rapidly identify adult patients with infection who are more likely to have poor 
outcomes. qSOFA is considered to be positive if the patient has at least 2 of the following 
clinical criteria:  respiratory rate of 22/min or greater, altered mentation (Glasgow Coma 
Scale of <15), or systolic blood pressure of 100 mm Hg or less.  
 
WHAT ARE THE POTENTIAL ADVANTAGES? 
  
There are potential advantages in the new definitions:  
 
 This was the first data-driven definitions set in which the domains of usefulness were 
used, helping to standardize concepts in the scenario of a heterogenous syndrome 
such as sepsis.  
 Consistency of language around definitions is likely to improve (severe sepsis and 
sepsis were commonly used interchangeably). 
 The use of variation in SOFA score might help to identify worsening organ 
dysfunction in patients who already have documented dysfunction. 
 SIRS criteria are no longer required for the diagnosis of sepsis. As approximately 10-
12% of patients with sepsis do not have ≥ 2 SIRS criteria3 (at least in the intensive 
care unit (ICU)), the now historic use of SIRS criteria alone would have missed some 
patients with sepsis. 
 The new qSOFA score uses signs such as high respiratory rate, low blood pressure 
and altered mental status that were found to be clinically relevant using a large 
database of patients with sepsis. Any one of these signs should be an alert to the 
bedside clinician to ‘think sepsis’, and as such qSOFA brings attention to the 
importance of any abnormal physiology in patients with infection. Altered mental 
status is increasingly recognized as a sensitive marker for severity of illness in sepsis. 
 qSOFA and a change in SOFA score may be better predictors of poor outcome than 
offered by previous definitions 
 The change may aid in the assessment of new therapies. 
 
WHAT ARE THE POTENTIAL DISADVANTAGES? 
 
There are also potential disadvantages in the new definitions:  
 
 Using the new definitions in the clinical environment is likely to present difficulty, 
particularly as the SOFA score has not historically been used outside of the ICU (nor 
is it in routine and continuous use in all ICUs). This reduces the content validity of the 
new definition of organ dysfunction as most patients present to the Emergency 
Department or deteriorate on a ward. Those stakeholders will not recognize SOFA as 
a standard of assessment of organ dysfunction. As a result, non-ICU stakeholders 
might fail to engage fully with the largely ICU-driven new definitions. 
 Complexity can lead to errors, which can lead to diagnosis and treatment variability. 
The current proposition adds burden to the data collection as well as for the bedside 
healthcare workers, since the complexity of calculating variations in six different 
organ dysfunction systems is high. Thus having SOFA variation as a definition also 
reduces its usefulness in the measurement burden, one of the relevant domains used to 
define usefulness of disease definitions.  
 In terms of predictive validity, the variation in the SOFA score (which now defines 
sepsis) was validated comparing its ROC curve against the ROC curve of two or more 
SIRS criteria alone, rather than the previous definition of severe sepsis being SIRS 
criteria plus at least one organ dysfunction. 
 There are major flaws in terms of construct validity. First, the current definition 
excludes patients with isolated hypotension or Glasgow 13-14 from the definition of 
sepsis as they will have a SOFA score of 1. Lactate is not part of the SOFA score, yet 
lactate is well documented as a sensitive marker of severity of illness in patients with 
infection, can identify ‘cryptic shock’ in patients who are normotensive, and the 
normalization of lactate levels with fluid resuscitation is a good prognostic indicator. 
As such lactate retains an important role in the risk stratification of patients with 
infection and in guiding initial fluid resuscitation as well as being a diagnostic 
criterion for septic shock. 
 Health professionals on the front line in many countries now use track-and-trigger 
early warning score systems (e.g. NEWS, PARS) as a standard of care in identifying 
potential deterioration or critical illness. Where used such scores, which are validated 
in their predictive values, have become the currency of communication around acuity 
of illness. To introduce a second aggregate score using similar variables with different 
thresholds (qSOFA) and which is specific to only one cause of deterioration not only 
adds complexity but also risks confusing organisational learning with potentially 
adverse consequence for patient safety in general. 
 The weight given to predictive validity instead of to construct validity in the new 
qSOFA score is an issue. Using two of the three variables of this score as a prompt to 
act (e.g. refer to Intensive Care, transport to hospital) selects a population with a high 
risk of death and this risk of death is var iable according to the different settings in 
which the score is applied. Additionally, the risk of death which is weighted 
acceptable, will vary according to their place of care, (out of hospital vs. in-hospital), 
the risk of not acting, and the ability to intervene effectively. Particularly in resource 
poor settings, but also in many high-income countries, the mortality rate associated 
with a qSOFA of 2 is unacceptably high to stand alone as a prompt to act. The 
requirement of two qSOFA criteria as a prompt to act might lead to the 
misunderstanding that patients with only one organ dysfunction or physiological 
derangement do not need timely appropriate escalation of care and treatment for their 
infection and organ dysfunction. This is not the intent of the new definition but it 
could be an unintended consequence. A single organ dysfunction or one qSOFA 
criterion attributable to sepsis warrants immediate diagnostic and therapeutic actions.  
 The predictive validity used to generate qSOFA resulted in a severity assessment 
score, which is now being misused as a screening tool. Even its role as a severity 
score was not submitted to proper prospective validation in different settings. Recent 
studies indicate that qSOFA lacks sensitivity4,5,6. Screening tools for sepsis require 
sensitivity to allow the capture of patients at risk of sepsis. Using qSOFA as a 
screening tool identifies patients with a high mortality and/or intensive care 
requirement- a qSOFA of 2 occurs at too high an acuity for many patients in hospital 
to first receive a higher level of care, and is of no value in determining whether a 
patient in the community requires hospital assessment. qSOFA is neither a diagnostic 
nor a screening tool for sepsis. At this moment, the qSOFA score cannot be 
recommended for wide scale use due to its lack of sensitivity. An unintended 
consequence of implementing this tool would be that those who do not fulfil its 
criteria might go without treatment. This is not its intended use. Patients with 
infection or sepsis should have their infection treated as usual; the subgroup of 
patients who have two qSOFA criteria most likely require escalated treatment in an 
intensive care unit if available.  
 Although we agree that the systemic inflammatory response syndrome criteria have a 
poor discriminant validity, SIRS still has an important role in identifying patients with 
infection who may benefit from antimicrobial therapy, fluids and additional screening 
for organ dysfunction. This approach has been used in many QI programmes with a 
positive impact on mortality reduction.  
 The definition of septic shock requires a laboratory test, which is not available in 
many parts of the world mostly in low and middle-income countries (LMIC). This 
will preclude the diagnosis of septic shock in these settings and will generate a 
discrepancy in the criteria used around the world- this may compromise the 
epidemiological assessment of the sepsis burden.  The Task Force, although 
acknowledging the issue, did not propose an alternative definition. The predictive 
validity of other signs of hypoperfusion was not assessed, thus they can not be used as 
substitutes for hyperlactatemia.  
 The introduction of Sepsis 3 requires co-ordination with local and/or national coding 
practices. 
 
THE IMPACT IN THE QUALITY IMPROVEMENT PROGRAMS  
 
Operationalization of the new definitions  
 
In terms of quality improvement initiatives, the major issue is the new definition of 
organ dysfunction. A variation in SOFA score is not a feasible tool to be used in the bedside 
identification of the potential septic patient. The broad definition of sepsis, the presence of a 
life threating organ dysfunction, should remain the basis of all QI initiatives. Thus, screening 
for early identification and treatment of patients with sepsis (formerly called severe sepsis) 
should continue essentially as previously recommended by SSC and seek the presence of any 
organ dysfunction. We are fully supportive of the recent SSC statement recommending that 
patients with sepsis (formerly called severe sepsis) should still be identified by the same 
organ dysfunction criteria (including lactate level greater than 2 mmol/L). The new 
definitions should not change the primary focus- of early sepsis identification and initiation 
of timely treatment- in the management of this vulnerable patient population. qSOFA should 
not be used as a screening tool for sepsis in wards or by emergency services before proper 
prospective validation.  
  
National incentives to improve sepsis  
 
Some countries have programmes and incentives to support improved sepsis 
management and enhance patient outcome. Achievement of agreed targets may have 
significant financial implications for hospitals under such programmes. Hospitals, other 
healthcare providers, commissioners and policy makers should ensure that any potential 
changes are co-ordinated with all the relevant stakeholders and that the targets and 
measurement processes are all aligned to ensure that the data is captured correctly and does 





The Task Force has made recommendations for coding based on the new definitions 
and ICD-10 codes. These need to be translated into practical instructions for clinical coders at 
a local or national level when sepsis-3 is being introduced to ensure data capture is optimised. 
Coders are not allowed to interpret laboratory data for organ dysfunction, or use SOFA scores 
to code for sepsis in patients with an infection diagnosis – coding for sepsis remains 
dependent on clinicians writing the diagnosis in the patient’s clinical notes.  
 
Change in sepsis population and impact on outcomes 
 
Sepsis improvement projects should consider how implementation of the new sepsis 
definitions may affect their outcomes, as changes in outcomes may well be related to a 
change in sepsis population rather than true improvements in recognition and care. For 
instance, the Task Force did not clarify how the diagnosis of septic shock should be made in 
settings where lactate measurement is not available. In some areas, patients with 
hypoperfusion in the absence of vasopressors might be scored (in our view) erroneously 
under the ‘sepsis’ label; in other areas the same patients might be coded as having septic 
shock. If patients in areas without the ability to measure hyperlactatemia are considered as 
having septic shock, the mortality comparison between settings will be compromised as in 
other settings vasopressors and hyperlactataemia will be required. If those patients are 
considered as having sepsis the incidence of septic shock in Low and Middle Income 
Countries will be artificially seen to drop and the mortality rate of non-shock sepsis will 
appear to rise. It is important that all stakeholders understand any changes, and how they will 
influence data on incidence, hospital length of stay, critical care admission rates, critical care 
length of stay and mortality rates. 
 
NEXT STEPS  
 
The release of the new definitions has created confusion among both front-line 
healthcare workers, who need to identify patients with sepsis early in the course of the 
disease; and quality improvement programs which need to educate, train, plan and effect 
change and measure performance. Quality improvement programs require training strategies 
on early detection and easily applicable screening tools. The proposed variation in SOFA 
score as a definition of organ dysfunction is not feasible to be used at the bedside. For the 
new proposed score, qSOFA, to be accepted into operational use it must be adequately 
prospectively validated, must be evaluated and show promise as a screening tool ra ther than 
merely a risk stratification tool, and a pathway must be offered.for the management of 
patients who are clearly unwell but who do not (yet) satisfy 2 qSOFA criteria. Some of these 
issues were discussed by the authors as limitations in the Sepsis 3.0 manuscript (ref). 
However, their statements were not sufficient to clarify how the new definitions can be used 
at bedside.  
 
Thus, our proposal is that an additional statement by the Sepsis 3 authors be issued in 
order to clarify some of these points as stated below.   
 
1. Different stakeholders might need to use different definitions of organ dysfunction. 
The bedside physician should provide prompt care to any patient with suspected 
infection who has any new organ dysfunction irrespective of the SOFA score. In 
quality improvement programs, the broad Sepsis 3 narrative definition of sepsis, 
which describes the presence of any life-threatening organ dysfunction, should be 
considered. This would include, for instance, patients with any one of a reduced level 
of consciousness, hypotension or hyperlactatemia, as all such patients require early 
recognition and treatment. Outside hospitals, strategies reflecting the need for a 
balance from specificity toward sensitivity whilst retaining the lack of requirement for  
laboratory tests will be needed. At the present time, a variation in SOFA score as a 
definition of organ dysfunction is more appropriate for use in clinical and 
epidemiological studies. 
 
2. qSOFA is not part of the definition and must not be used as a screening tool for 
patients with sepsis. It should not become part of clinical practice before it is properly 
and prospectively evaluated in the different clinical settings both in terms of its 
predictive validity and construct validity. In settings with high mortality rates, 
particularly in low and middle income countries, screening for sepsis should be based 
on sensitive tools with a response graded according to acuity to allow earlier 
recognition.  
 
3.  In settings where lactate measurements are not available, the diagnosis of septic 
shock is compromised. The Task Force acknowledged that the voting process for the 
septic shock definition was a tight one. Only a slight majority of the members voted 
for having lactate as an obligatory requirement (the AND choice) instead of an 
alternative to vasopressor requirement (the OR choice). They recognized that this 
issue needed to be revisited soon. Meanwhile, the Task Force needs to clearly state 
how the diagnosis of septic shock should be made in settings where lactate is not 
available.  
 
4. In future discussions, to further develop and to overcome the current controversies, it 
is important to be more inclusive in terms of a global perspective and stronger 
involvement of all stakeholders, representative not only of the spectrum of healthcare 
providers but also of different cultures, economic environments and gender, which 
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